Loading news...
DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Daxor (NASDAQ: DXR - Get Free Report) and Quest Diagnostics (NYSE: DGX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 1.3% of Daxor shares are
Quest Diagnostics (NYSE: DGX - Get Free Report) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of $2.36 per share and revenue of $2.7534 billion for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning
New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma).
Truist Financial Corp cut its holdings in shares of Quest Diagnostics Incorporated (NYSE: DGX) by 19.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,542 shares of the medical research company's stock after selling 10,432 shares during the quarter. Truist Financial Corp's
Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen research firms that are currently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average
Alpha Cubed Investments LLC grew its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 1,589.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,190 shares of the medical research company's stock after acquiring an additional 66,975 shares during the
Quest Diagnostics gets reaffirmed as a buy for the 3rd time in a row. Key bullish drivers include organic growth, macro demand, strong profit margins among peers, and an investment-grade view from Fitch and S&P. The key peer in the US of Labcorp, it is also a proven dividend grower.
Compass Wealth Management LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE: DGX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,564 shares of the medical research company's stock, valued at approximately $679,000. Several other hedge funds
SECAUCUS, N.J., Jan. 21, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been named to the Fortune® magazine 2026 World's Most Admired Companies™ list, for the 12th consecutive year.
Dynasty Wealth Management LLC acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 9,748 shares of the medical research company's stock, valued at approximately $1,858,000. A
Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership.
Guru Stock PicksLarry Robbins has made the following transactions:Add in MYGN by 7.71%Stock News Trump floats 10% cap on card APRs: President Trump proposed a o
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SG Americas Securities LLC lessened its position in Quest Diagnostics Incorporated (NYSE: DGX) by 46.4% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,622 shares of the medical research company's stock after selling 19,597 shares during the period. SG
Allspring Global Investments Holdings LLC grew its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 50.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,775 shares of the medical research company's stock after acquiring an additional 5,297 shares during the quarter.